Henry Meds vs Sequence 2026: GLP-1 Weight Loss Programs Compared
Henry Meds vs Sequence (now WW Med+) for GLP-1 weight loss in 2026. Compare pricing, medications, provider models, and clinical support. See how Trimi's compounded semaglutide compares to both.
Written by Trimi Medical Team. Medically reviewed by Dr. Sean Arora, MD. Our team updates competitor comparisons when pricing, medication access, or provider policies change so patients can evaluate GLP-1 options with current data.
Quick links: Semaglutide treatment, tirzepatide treatment, Henry Meds side effects, and Sequence side effects.
More on GLP-1 Provider Comparisons
Henry Meds vs Sequence: Quick Overview
If you are comparing Henry Meds vs Sequence for GLP-1 weight loss in 2026, you are evaluating two telehealth platforms that occupy different positions in the GLP-1 market. Henry Meds has built its reputation on competitive pricing and streamlined access to compounded semaglutide and compounded tirzepatide through licensed providers and accredited compounding pharmacies. Sequence is now WW Med+, with medical services provided through WeightWatchers Clinic: as of October 2026, joinsequence.com redirects to WeightWatchers, which states that it only prescribes FDA-approved medications. Compounded preparations are not FDA-approved and are not the same products as brand-name medications. The platforms also differ in what you pay, the level of clinical programming around your treatment, and the provider model guiding your care.
What Are GLP-1 Medications?
GLP-1 receptor agonists are a class of medications originally developed for type 2 diabetes that have demonstrated significant weight loss efficacy. Semaglutide (the active ingredient in Wegovy and Ozempic) and tirzepatide (the active ingredient in Zepbound and Mounjaro) work by mimicking natural incretin hormones that regulate appetite, slow gastric emptying, and improve insulin sensitivity. In clinical trials, semaglutide produced average weight loss of approximately 15 percent of body weight (Wilding et al., NEJM, 2021), while tirzepatide, a dual GIP/GLP-1 agonist, produced up to 22.5 percent (Jastreboff et al., NEJM, 2022). Those trials studied the FDA-approved brand products. Compounded semaglutide and tirzepatide are prepared by state-licensed pharmacies against an individual prescription and are not FDA-approved as drugs. For a full explanation, see our cheapest GLP-1 injections guide.
Henry Meds is a direct-to-consumer telehealth platform that has gained significant market share through aggressive pricing on compounded GLP-1 medications. Their model is medication-focused: patients complete a web-based health assessment, receive a provider consultation, and get medications shipped directly. Henry Meds charges separately for consultations ($49 to $99) on top of monthly medication costs, and their pricing tiers range broadly depending on the medication and dose level. The platform prioritizes efficient medication access over comprehensive clinical programming.
WW Med+ (formerly Sequence) takes a different approach: it is a membership program, and as of October 2026 WeightWatchers states that WW Med+ plans auto-renew for 12-month or 6-month periods unless canceled and that the membership does not include the cost of GLP-1 medications.
We include Trimi in this comparison because at $99 per month for compounded semaglutide and $125 per month for compounded tirzepatide, it represents a meaningfully different price point that patients evaluating Henry Meds should consider. Trimi combines specialized weight management providers with pricing that undercuts Henry Meds substantially, without sacrificing clinical focus. Trimi's preparations are compounded and not FDA-approved, unlike the brand-name medications prescribed through WW Med+.
Head-to-Head Comparison Table
The following table compares Henry Meds, Sequence, and Trimi across the factors that matter most for patients choosing a GLP-1 weight loss provider. All pricing reflects data observed in early 2026.
| Factor | Henry Meds | Sequence (now WW Med+) | Trimi |
|---|---|---|---|
| Semaglutide Price | $199 - $349/mo | FDA-approved only, such as the Wegovy pill; billed separately from membership | $99/mo |
| Tirzepatide Price | $299 - $449/mo | FDA-approved only, such as Zepbound; billed separately from membership | $125/mo |
| Consultation Fee | $49 - $99 | WW Med+ membership fee; see WeightWatchers' pricing page | Free |
| Contract Required | Monthly | 6- or 12-month plans that auto-renew | Annual plan: 12-month commitment; month-to-month plan available |
| Platform Type | Web-based | Check WeightWatchers' current program details | Web + messaging |
| Provider Model | Medication-focused | Provider-led program | Metabolic health specialist |
| Clinical Oversight | Standard telehealth | Through WeightWatchers Clinic | Dedicated weight management |
| Shipping | Included | Check the medication and pharmacy terms | Free included |
| Insurance Coordination | No | Commercial insurance plans only | No |
| 12-Mo Semaglutide Total | $2,388 - $4,188+ | Membership plus separately billed medication | $1,188 |
| 12-Mo Tirzepatide Total | $3,588 - $5,388+ | Membership plus separately billed medication | $1,500 |
Pricing Note
Telehealth pricing changes frequently. Check current offers on each provider's website. Henry Meds' consultation fee adds $49 to $99 to the first month that is not reflected in their advertised monthly rate. The figures above reflect standard plan pricing observed in early 2026. Always verify current rates directly on each provider's website before committing.
Pricing Comparison: What You Actually Pay Over 12 Months
Pricing is the most immediately visible difference between Henry Meds and Sequence, and it reflects their fundamentally different value propositions. Henry Meds positions itself as a competitive-price medication access platform, while WW Med+ (formerly Sequence) is a membership program with brand-name medication billed separately. Henry Meds is significantly more expensive than providers like Trimi that offer the same active medications at lower price points. GLP-1 therapy is not a short-term commitment, most patients need 6 to 12 months of continuous treatment to reach their weight loss goals, and many continue maintenance dosing indefinitely. Monthly cost differences compound into thousands of dollars over a typical treatment course.
Henry Meds prices compounded semaglutide between approximately $199 and $349 per month depending on dose tier and plan structure. Their tirzepatide pricing ranges from $299 to $449 per month. On top of these monthly medication costs, Henry Meds charges a separate consultation fee of $49 to $99 for initial provider evaluations. This means a new Henry Meds patient starting semaglutide could pay $248 to $448 in their first month before any medication arrives. Over 12 months on semaglutide, a Henry Meds patient at the mid-range pays approximately $2,388 to $4,188 plus the initial consultation fee. For tirzepatide, the 12-month total ranges from $3,588 to $5,388 or more.
Sequence is now WW Med+, with medical services provided through WeightWatchers Clinic, and as of October 2026 WeightWatchers states that it only prescribes FDA-approved medications. WeightWatchers lists WW Med+ at $25 for the first month, then $74 per month on a 12-month plan or $84 per month on a 6-month plan; plans auto-renew, and the membership does not include the cost of GLP-1 medications. Check WeightWatchers' current pricing page for self-pay brand-name medication costs.
At Trimi, compounded semaglutide costs $99 per month and compounded tirzepatide costs $125 per month. There is no consultation fee, no enrollment fee, and no membership fee. A patient taking semaglutide for 12 months at Trimi pays $1,188 total. The same patient at Henry Meds pays $2,388 to $4,188 or more. For patients weighing the cheapest GLP-1 options in 2026, this pricing gap is substantial enough to influence provider selection for most budgets.
Watch for Hidden Costs
When comparing GLP-1 providers, factor in consultation fees, dose escalation pricing, shipping charges, and cancellation penalties. Henry Meds' separate $49 to $99 consultation fee is easy to overlook when comparing advertised monthly rates. A provider offering flat $99 per month pricing at all dose tiers with no additional fees may cost significantly less annually than Henry Meds.
Medications and Access: What Each Platform Prescribes
Henry Meds prescribes compounded versions of the two most studied GLP-1 weight loss medications, semaglutide and tirzepatide, while Sequence, now WW Med+ through WeightWatchers Clinic, prescribes only FDA-approved medications as of October 2026. Wegovy, Ozempic, Zepbound, and Mounjaro are FDA-approved finished drugs made by their manufacturers. Compounded preparations are made by state-licensed pharmacies against an individual prescription, are not FDA-approved as drugs, and have not been studied in their own clinical trials. This comparison is between a compounded-medication platform and a brand-name medication program, not between two sources of the same product.
Henry Meds offers both compounded semaglutide and compounded tirzepatide as their primary weight loss offerings. Their medication-focused model means the platform is built around getting prescriptions written and medications shipped efficiently. Henry Meds works with compounding pharmacy partners to maintain supply, and medications are delivered directly to patients. The platform handles refills and dose adjustments through their web-based system, though the depth of clinical guidance around those adjustments varies by the individual provider assigned to your case.
WW Med+ (formerly Sequence) does not offer compounded semaglutide or tirzepatide: as of October 2026, WeightWatchers states that it only prescribes FDA-approved medications and lists self-pay options for the Wegovy pill and for Zepbound vials and KwikPens dispensed through LillyDirect pharmacy, with a separate WW Med+ membership fee required. WeightWatchers also says many medications are covered by insurance, and its insurance coordinators currently work only with commercial insurance plans.
Trimi offers both compounded semaglutide and compounded tirzepatide as core offerings with consistent availability. Because Trimi focuses specifically on metabolic health and GLP-1 therapy, medication supply continuity is a central operational priority. Patients who start with semaglutide and later want to transition to tirzepatide, or vice versa based on response and tolerability - can do so seamlessly within the same platform and provider relationship. For patients researching side effect profiles, our guides on Henry Meds side effects and Sequence side effects cover what to expect from each platform's medication protocols.
Provider Model Comparison: Medication Access vs Clinical Program
The provider model is where Henry Meds and Sequence diverge most significantly, and it represents the core trade-off patients must evaluate when choosing between these platforms. GLP-1 therapy involves dose titration decisions, side effect management, treatment duration planning, and ongoing clinical monitoring, all of which benefit from provider expertise and engagement. The question is how much clinical infrastructure you need around your treatment and how much you are willing to pay for it.
Henry Meds operates primarily as a medication access platform. Patients complete a web-based health questionnaire, a licensed provider reviews the submission, and if appropriate, a prescription is issued. The initial consultation may include a video or phone call depending on the plan, which is why Henry Meds charges the separate $49 to $99 consultation fee. After the initial prescription, ongoing provider interactions are generally limited to prescription renewals and basic dose adjustment requests. This model works well for patients who understand GLP-1 therapy, are comfortable self-managing common side effects, and primarily need affordable medication access rather than comprehensive clinical guidance. For patients who want to learn more about what to expect, our Henry Meds side effects guide covers the common issues patients report.
WW Med+ (formerly Sequence) is a membership program with medical services provided through WeightWatchers Clinic. As of October 2026, WeightWatchers states that it only prescribes FDA-approved medications, that WW Med+ plans auto-renew unless canceled, and that the membership does not include the cost of GLP-1 medications.
Trimi's model falls between these two approaches in structure but delivers dedicated weight management expertise at a lower price point than Henry Meds. Trimi providers focus specifically on metabolic health and GLP-1 therapy, providing the clinical specialization that generalist platforms lack. Patients can communicate directly with their care team for dose questions, side effect guidance, and treatment adjustments through Trimi's web and messaging system without additional fees. This focused approach means patients get knowledgeable clinical support from providers who manage GLP-1 cases daily, not occasionally between other health categories.
What Provider Specialization Means for You
Board certification in obesity medicine indicates advanced formal training in metabolic health. However, provider specialization and clinical experience with GLP-1 therapy specifically are equally important for day-to-day treatment management. A provider who manages hundreds of GLP-1 patients monthly develops pattern recognition for dose timing, side effect mitigation, and treatment adjustments that benefits individual patients regardless of their board certification status. The best outcome comes from a provider who combines metabolic health knowledge with high-volume GLP-1 clinical experience.
Clinical Evidence: The Medication Drives Results, Not the Platform
A critical point that sometimes gets lost in provider comparisons: your weight loss outcomes are determined by the medication, the dose, and your adherence to treatment, not which telehealth brand delivered the prescription. The clinical evidence supporting GLP-1 medications for weight loss is extensive and entirely platform-independent. Neither Henry Meds nor Sequence has proprietary medications. Henry Meds prescribes compounded preparations from licensed compounding pharmacies, while WW Med+ (formerly Sequence) prescribes FDA-approved brand-name medications.
The STEP 1 trial, published by Wilding et al. in the New England Journal of Medicine in 2021, randomized 1,961 adults with obesity or overweight to semaglutide 2.4 mg weekly or placebo. Over 68 weeks, participants receiving semaglutide lost an average of 14.9 percent of their body weight compared to 2.4 percent in the placebo group. This landmark study established semaglutide as one of the most effective pharmaceutical interventions for weight management ever studied, with efficacy far exceeding older weight loss medications and rivaling surgical outcomes for some patients.
The SURMOUNT-1 trial, published by Jastreboff et al. in the New England Journal of Medicine in 2022, evaluated tirzepatide in 2,539 adults with obesity. The highest dose group (15 mg weekly) achieved an average weight reduction of 22.5 percent of body weight over 72 weeks, the largest average weight loss ever recorded in a pharmaceutical obesity trial. Tirzepatide's dual mechanism as both a GIP and GLP-1 receptor agonist produces additive metabolic benefits beyond what GLP-1 stimulation alone achieves, including greater improvements in insulin sensitivity and cardiovascular risk markers.
Additional evidence from the SELECT cardiovascular outcomes trial (Lincoff et al., NEJM, 2023) demonstrated that semaglutide reduced major adverse cardiovascular events by 20 percent in adults with overweight or obesity and established cardiovascular disease. The STEP 5 trial showed sustained weight loss maintenance over 2 years of continued semaglutide therapy. These results reinforce that GLP-1 medications deliver robust, clinically meaningful outcomes that extend well beyond weight reduction alone.
These trials studied the FDA-approved brand products. Compounded semaglutide and tirzepatide are prepared by state-licensed pharmacies against an individual prescription, are not FDA-approved as drugs, and have not been studied in their own clinical trials, so these results should not be read as a promise about a compounded preparation. Among telehealth platforms prescribing compounded preparations, what a good provider adds is clinical guidance on dose titration, side effect management, and long-term treatment strategy. That guidance should not cost thousands of dollars more per year when providers like Trimi deliver it at $99 per month.
Evidence in Context
Clinical trial results represent averages across diverse study populations. Individual outcomes vary based on starting weight, metabolic factors, medication adherence, dose achieved, diet, and physical activity. Some patients exceed trial averages while others fall below them. Consistent treatment over months, not weeks, is what the evidence supports for meaningful, sustained weight loss. Compounded preparations are not FDA-approved, and differences in formulation or preparation should not be dismissed as a matter of branding.
Where Henry Meds Has the Edge
Henry Meds has legitimate advantages for certain patient profiles, particularly those who prioritize medication access efficiency and lower relative pricing within the premium telehealth segment.
Streamlined medication access model that gets prescriptions filled and shipped quickly
Broader tirzepatide dosing options and pricing tiers offering more flexibility for dose escalation
Simpler platform focused on weight loss rather than a multi-service health program
Growing competitive position that may continue to drive pricing improvements across the market
WW Med+ (Formerly Sequence): Program Details
WW Med+ suits patients who want FDA-approved brand-name medication, with the WW Med+ membership and GLP-1 medication billed separately.
Prescribes only FDA-approved medications as of October 2026, with self-pay options for the Wegovy pill and for Zepbound vials and KwikPens dispensed through LillyDirect pharmacy
Insurance coordinators who, as of October 2026, work only with commercial insurance plans; WeightWatchers says many medications are covered by insurance
Shared Limitations of Both Platforms
Despite their respective strengths, Henry Meds and Sequence share fundamental limitations that patients should consider before committing to either platform for long-term GLP-1 therapy.
Henry Meds charges significantly more than specialized providers like Trimi for the same active medications
Henry Meds' medication-only model may leave patients without adequate clinical guidance during side effects
Henry Meds' 12-month costs exceed $2,300 for semaglutide, more than double Trimi's $1,188 annual total
Promotional and introductory pricing can obscure true long-term treatment costs at either platform
How Trimi Compares
For patients whose primary criteria are effective GLP-1 medication at the lowest sustainable price with quality clinical support, Trimi addresses the key cost and specialization gaps in the Henry Meds model. At $99 per month for compounded semaglutide and $125 per month for compounded tirzepatide on the 12-month annual plan, Trimi's everyday pricing undercuts Henry Meds without requiring promotional codes or limited-time introductory offers.
Semaglutide at $99/mo, $100 to $250 less per month than Henry Meds at comparable doses
Tirzepatide at $125/mo, $174 to $324 less per month than Henry Meds
No consultation fee, saving the $49 to $99 that Henry Meds charges for initial evaluation
No membership fee, and the annual plan is backed by a 6-month money-back policy
Specialized weight management providers, clinical focus that Henry Meds lacks
5-7 day delivery, faster than the typical timelines at Henry Meds
Annual savings of $1,200 to $3,000 compared to Henry Meds over a 12-month treatment course
The core argument is straightforward: the medication produces the results, and Trimi and Henry Meds both prescribe compounded preparations. Henry Meds gives you medication access without much clinical support. WW Med+ (formerly Sequence) prescribes FDA-approved brand-name medications, billed separately from its membership. Trimi gives you dedicated weight management clinical support at a lower price than Henry Meds. For most patients, that combination, specialized care plus affordable pricing, is the optimal balance. For patients considering switching, our guides on canceling Henry Meds and canceling Sequence walk through the transition process step by step.
The Bottom Line
Henry Meds and Sequence represent two legitimate but fundamentally different approaches to GLP-1 telehealth. Henry Meds is the better choice between these two if you want compounded medication. Sequence, now WW Med+ through WeightWatchers Clinic, is the better choice if you want FDA-approved brand-name medication within a structured program, with the WW Med+ membership and GLP-1 medication billed separately.
However, Henry Meds does not justify its pricing when evaluated against the broader compounded GLP-1 provider market. Among compounding platforms, compounded semaglutide is compounded semaglutide regardless of which telehealth brand ships it. Trimi offers the same active medications at $99 per month for semaglutide and $125 per month for tirzepatide, with no consultation fees, no membership fee, and providers who specialize in weight management. Over a 12-month treatment course, the savings compared to Henry Meds are meaningful enough to fund additional health investments or simply reduce the financial burden of long-term treatment.
We encourage patients to verify current pricing directly on each platform's website before committing. Compare total annual cost at your expected maintenance dose, not introductory prices at the lowest dose. For a broader view of the GLP-1 provider landscape, see our cheapest GLP-1 injections in 2026 and our guide to semaglutide treatment at Trimi.
Frequently Asked Questions
Is Henry Meds or Sequence cheaper for GLP-1 medications in 2026?
Sequence is now WW Med+ through WeightWatchers Clinic, which as of October 2026 prescribes only FDA-approved medications and bills GLP-1 medication separately from its membership, so its costs are not directly comparable with Henry Meds' compounded semaglutide at $199 to $349 per month; see WeightWatchers' current pricing page. Henry Meds also charges a separate consultation fee of $49 to $99 in the first month. Henry Meds does not match Trimi's $99 per month semaglutide pricing, which includes consultation and shipping at no extra cost.
Does Sequence offer better medical oversight than Henry Meds?
Sequence is now WW Med+, with medical services provided through WeightWatchers Clinic, which as of October 2026 states that it only prescribes FDA-approved medications; check WeightWatchers' current program pages for how its clinical support is structured. Henry Meds uses a more streamlined web-based consultation model focused on medication access rather than comprehensive clinical programming.
Do Henry Meds and Sequence prescribe the same medications?
No. Henry Meds focuses primarily on compounded semaglutide and compounded tirzepatide prepared by accredited compounding pharmacies. Sequence is now WW Med+ through WeightWatchers Clinic, and as of October 2026 WeightWatchers states that it only prescribes FDA-approved medications, such as the Wegovy pill and Zepbound, with GLP-1 medication billed separately from the WW Med+ membership. Brand-name products are FDA-approved finished drugs, while compounded preparations are not FDA-approved as drugs.
Can I switch from Henry Meds to Sequence or vice versa?
Yes, patients can switch between GLP-1 providers at any time. Complete the new provider's health assessment and share your current medication, dosage, and treatment history. A provider at the new platform will evaluate your current medication and dose and determine whether to prescribe; compounded and brand-name products should not be assumed interchangeable. Review any contractual commitments or prepaid balances with your current provider before switching. Our guides on canceling Henry Meds and canceling Sequence cover the transition process in detail.
Which provider is better for tirzepatide specifically?
Henry Meds prices compounded tirzepatide between $299 and $449 per month through accredited pharmacies. Sequence is now WW Med+ through WeightWatchers Clinic, which as of October 2026 prescribes only FDA-approved medications, so it lists self-pay Zepbound dispensed through LillyDirect pharmacy rather than compounded tirzepatide, with a separate WW Med+ membership fee required. For patients prioritizing cost, Trimi offers compounded tirzepatide at $125 per month with dedicated weight management providers, making it substantially more affordable than Henry Meds.
Are Henry Meds and Sequence legitimate telehealth providers?
Both Henry Meds and Sequence are legitimate telehealth platforms that connect patients with licensed healthcare providers who can prescribe GLP-1 medications. Henry Meds has grown rapidly in the direct-to-consumer weight loss space with competitive pricing. Henry Meds works with accredited compounding pharmacies, while WW Med+ (formerly Sequence) states that it only prescribes FDA-approved medications.
What is the most affordable alternative to Henry Meds?
Trimi offers transparent pricing, with compounded semaglutide at $99 per month and compounded tirzepatide at $125 per month. There are no consultation fees, no membership fee requirements, and free shipping is included. Over 12 months, a patient on semaglutide would pay $1,188 at Trimi compared to $2,388 to $4,188 at Henry Meds.
Sources & References
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
- Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232.
- Henry Meds, official website and pricing information.
- Sequence, official website and pricing information.
- FDA guidance on drug compounding regulations and pharmacy standards.
- NIDDK overview of prescription medications for overweight and obesity.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program. Trimi is a competitor to both Henry Meds and Sequence, this comparison aims to be fair and balanced, but readers should be aware of our perspective when evaluating the information presented. Individual results vary. GLP-1 medications require a prescription and are not appropriate for everyone.